tempol (MBM-02) / DMK Pharma, Matrix Biomed 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
  • ||||||||||  tempol (MBM-02) / DMK Pharma, Matrix Biomed
    Trial termination:  Study to Evaluate the Effects of Tempol (MBM-02) in COVID-19 Patients. (clinicaltrials.gov) -  Dec 6, 2022   
    P2/3,  N=248, Terminated, 
    Recruiting --> Terminated; Study did not demonstrate statistical significance of its primary endpoint of clinical resolution of COVID-19 symptoms at day 14 versus placebo
  • ||||||||||  tempol (MBM-02) / DMK Pharma, Matrix Biomed
    Enrollment open, Trial completion date, Trial primary completion date:  Study to Evaluate the Effects of Tempol (MBM-02) in COVID-19 Patients. (clinicaltrials.gov) -  Aug 26, 2021   
    P2/3,  N=248, Recruiting, 
    Recruiting --> Terminated; Study did not demonstrate statistical significance of its primary endpoint of clinical resolution of COVID-19 symptoms at day 14 versus placebo Not yet recruiting --> Recruiting | Trial completion date: Jan 2022 --> Sep 2022 | Trial primary completion date: Dec 2021 --> Jun 2022
  • ||||||||||  tempol (MBM-02) / DMK Pharma, Matrix Biomed
    Trial initiation date:  Study to Evaluate the Effects of Tempol (MBM-02) in COVID-19 Patients. (clinicaltrials.gov) -  Aug 18, 2021   
    P2/3,  N=248, Not yet recruiting, 
    Not yet recruiting --> Recruiting | Trial completion date: Jan 2022 --> Sep 2022 | Trial primary completion date: Dec 2021 --> Jun 2022 Initiation date: May 2021 --> Aug 2021